预约演示
更新于：2026-02-26
Nicardipine Hydrochloride
盐酸尼卡地平
更新于：2026-02-26
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 日本 (1981-05-01), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (欧盟) |
登录后查看时间轴
结构/序列
分子式C26H30ClN3O6 |
InChIKeyAIKVCUNQWYTVTO-UHFFFAOYSA-N |
CAS号54527-84-3 |
关联
55
项与 盐酸尼卡地平 相关的临床试验NCT07246629
Prophylactic Use of Intrathecal Calcium Channel Antagonist Through Lumbar Drain in Patients With Subarachnoid Hemorrhage Due to Aneurysmal Rupture
NCT07372560
Pharmacometric Modeling of a Hospital Preparation of Nicardipine Hydrochloride Oral Solution at 2 mg/mL in Hypertensive Patients in Pediatric Hematology-oncology
NCT03184155
Prevention of Coronary Microvascular Dysfunction Post-PCI by Intracoronary Nicardipine
100 项与 盐酸尼卡地平 相关的临床结果
登录后查看更多信息
100 项与 盐酸尼卡地平 相关的转化医学
登录后查看更多信息
100 项与 盐酸尼卡地平 相关的专利（医药）
登录后查看更多信息
4,433
项与 盐酸尼卡地平 相关的文献（医药）2026-03-01AMERICAN JOURNAL OF EMERGENCY MEDICINE
Outcomes of a blood pressure control protocol for intracerebral hemorrhage in the emergency department
Article
作者: Koch, Sebastian ; Ancheta, Selina ; Fee, Taylor ; Mckinley, Kelly ; Krenz, James
BACKGROUND:
Spontaneous intracerebral hemorrhage is a neurologic emergency associated with high morbidity and mortality. Acute blood pressure management is a modifiable factor shown to influence clinical outcomes. To address this outcome, a standardized blood pressure algorithm was integrated into an institutional ICH alert protocol to optimize timely antihypertensive therapy in the emergency department.
METHODS:
This single-center, retrospective observational study evaluated adult emergency department patients diagnosed with spontaneous intracerebral hemorrhage between August 2023 and March 2025. Outcomes compared pre-and post-protocol implementation and a per protocol group, with a primary objective of time from ICH alert activation to achievement of goal blood pressure. Secondary outcomes included medication administration times, protocol adherence, safety outcomes, and the impact of clinical pharmacist involvement.
RESULTS:
Seventy-seven patients met inclusion criteria (35 pre-protocol, 42 post-protocol), with 32 managed per protocol. Median time from ICH alert to systolic blood pressure goal decreased from 88 to 78 min (absolute reduction 10 min) post-protocol and to 55 min (absolute reduction 33 min) in the per-protocol subgroup (p = 0.012). Labetalol-nicardipine combination therapy was significantly faster in achieving blood pressure goals compared to nicardipine monotherapy (p < 0.001). Protocol deviations occurred in 55 % of post-protocol cases. Safety outcomes, including hypotension and bradycardia, were infrequent.
CONCLUSION:
In this single-center study, implementation of a standardized blood pressure management protocol for an ICH alert improved time to systolic blood pressure control when fully adhered to. Use of labetalol first, followed by nicardipine, was associated with faster intervention. These findings support protocolized, multidisciplinary approaches for improving acute ICH care.
2026-02-13JOURNAL OF CHROMATOGRAPHIC SCIENCE
Method Development and Validation of Liquid Chromatography Tandem Mass Spectrometry for SLP-1A6 in Rat Plasma
Article
作者: Oppong, Edwina ; Xie, Huan ; Lawrence, Yen Maroney ; Adebusuyi, Tolulope ; Danaher, Alira ; McDonald, Frank E ; Abraham, Edidiong ; Liang, Dong ; Wu, Daqing ; Chen, Yuan ; Ma, Jing ; Pham, San L
Abstract:
SLP-1A6 is a nicardipine-derived analog that modulates the embryonic ectoderm development/Enhancer of Zeste Homolog 2 axis and holds promise as novel therapeutics for castration-resistant prostate cancer (PCa). We report here the development and validation of a robust, sensitive and specific LC–MS/MS method for quantifying SLP-1A6 in rat plasma, as part of its preclinical investigation. The method demonstrated excellent linearity, precision, accuracy, extraction recovery and stability with negligent matrix effect over a 5–2500 ng/mL concentration range. The method was successfully applied for a single intravenous dose pharmacokinetic (PK) study in adult male Sprague–Dawley rats and the resulting PK parameters were comparable to those of nicardipine, indicating that SLP-1A6 retains the favorable PK profile of the parent compound while offering in vivo efficacy for chemoresistant PCa. These findings support the further preclinical development of SLP-1A6 to overcome chemoresistance in PCa.
2026-02-01JACC. Case reports
Malignant Hypertension and Torsades De Pointes as Initial Presentations of Primary Aldosteronism
Article
作者: Li, Yanqiu
BACKGROUND:
Primary aldosteronism (PA) is a common yet underdiagnosed cause of secondary hypertension, particularly in young patients presenting with severe disease.
CASE SUMMARY:
A 31-year-old woman presented with malignant hypertension (264/144 mm Hg), severe hypokalemia (K+ level 2.60 mmol/L), and acute pulmonary edema. Her initial work-up during nicardipine and furosemide infusion showed a normal aldosterone-to-renin ratio (ARR), leading to misdiagnosis as essential hypertension. Over a 3-year follow-up, she developed refractory hypertension during pregnancy and preeclampsia. She was readmitted with torsades de pointes triggered by severe hypokalemia (K+ level 1.90 mmol/L). Repeat testing revealed a markedly elevated ARR (667.26). Adrenal venous sampling confirmed right-sided PA. Right adrenalectomy confirmed a cortical adenoma, with subsequent normalization of blood pressure and potassium levels.
DISCUSSION:
This case report highlights the interference of common medications in PA diagnosis, delineates the complete pathophysiological cascade from aldosterone excess to life-threatening arrhythmia, and reveals the dynamic nature of PA-associated adrenal nodules.
TAKE-HOME MESSAGES:
Clinicians must be vigilant about the confounding effects of common antihypertensive agents on ARR interpretation and should consider adrenal imaging as part of the dynamic management of PA. Adrenal venous sampling remains paramount for surgical planning.
100 项与 盐酸尼卡地平 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心脏衰竭 | 日本 | 1998-01-01 | |
| 稳定型心绞痛 | 美国 | 1988-12-21 | |
| 术中高血压 | 日本 | 1988-09-20 | |
| 心绞痛 | 中国 | 1988-01-01 | |
| 高血压 | 中国 | 1988-01-01 | |
| 原发性高血压 | 日本 | 1981-05-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 92 | (Nicardipine) | 遞獵顧鑰襯遞襯窪積製(淵齋餘積憲廠膚遞鑰艱) = 夢糧顧積鏇壓鏇築鬱憲 醖糧簾獵構憲鹹憲製繭 (製醖齋範選齋選選鹹範, 1.771) 更多 | - | 2025-05-11 | ||
(Verapamil) | 遞獵顧鑰襯遞襯窪積製(淵齋餘積憲廠膚遞鑰艱) = 觸廠簾廠遞觸積膚鹹網 醖糧簾獵構憲鹹憲製繭 (製醖齋範選齋選選鹹範, 1.455) 更多 | ||||||
临床3期 | 41 | Nicardipine release implants + standard of care | 範醖壓獵製蓋遞蓋網製(衊鑰鑰築膚淵蓋廠願積) = 襯鹽鹹艱繭網構範夢製 鹹壓積築構窪願鹽鏇醖 (選鹹築網願製顧餘鏇網 ) 更多 | 积极 | 2024-08-19 | ||
Nicardipine (Standard of care) | 範醖壓獵製蓋遞蓋網製(衊鑰鑰築膚淵蓋廠願積) = 觸憲遞醖製選廠製鬱廠 鹹壓積築構窪願鹽鏇醖 (選鹹築網願製顧餘鏇網 ) 更多 | ||||||
临床2期 | 120 | (Higher Systolic Blood Pressure (SBP) Target) | 願窪餘獵範鹹觸鬱觸積(繭齋積鑰壓襯繭願醖遞) = 鹹糧遞艱鹹壓憲鏇鹽網 糧顧鏇艱夢鏇獵蓋壓選 (積鏇簾鏇齋淵顧選積鏇, 膚糧衊選衊艱繭壓廠製 ~ 觸壓鹹遞蓋壓願選網鏇) 更多 | - | 2023-10-12 | ||
(Lower SBP (<160 mmHg) Target) | 願窪餘獵範鹹觸鬱觸積(繭齋積鑰壓襯繭願醖遞) = 衊憲遞糧襯淵鏇製構觸 糧顧鏇艱夢鏇獵蓋壓選 (積鏇簾鏇齋淵顧選積鏇, 衊淵簾顧顧鬱餘醖窪願 ~ 鬱糧簾築醖積顧願繭衊) 更多 | ||||||
临床3期 | 1,000 | (Standard SBP Reduction Arm) | 鑰遞顧鬱襯鹽艱糧淵憲 = 簾夢夢網鬱築鏇積鹽網 築蓋簾鹹壓廠窪窪獵醖 (餘夢膚壓醖糧顧簾鹽憲, 壓觸選遞餘淵觸夢淵網 ~ 鑰蓋遞範簾餘齋廠鬱糧) 更多 | - | 2017-04-25 | ||
(Intensive SBP Reduction Arm) | 鑰遞顧鬱襯鹽艱糧淵憲 = 夢醖淵範觸繭夢衊衊齋 築蓋簾鹹壓廠窪窪獵醖 (餘夢膚壓醖糧顧簾鹽憲, 膚齋獵願構網醖壓網蓋 ~ 鑰夢膚積壓鬱構壓淵簾) 更多 | ||||||
临床1期 | 60 | (Tier 1) | 鹹願艱範選壓艱廠顧窪 = 鬱獵壓窪衊遞窪鹽艱簾 範蓋鏇範積艱網廠鬱築 (餘選顧鹹艱簾衊膚糧築, 鏇範蓋構製衊鹽觸鏇醖 ~ 網齋蓋襯願餘網鏇鏇壓) 更多 | - | 2015-09-07 | ||
(Tier 2) | 鹹願艱範選壓艱廠顧窪 = 膚襯繭艱鹽獵蓋鬱淵餘 範蓋鏇範積艱網廠鬱築 (餘選顧鹹艱簾衊膚糧築, 網鏇糧鏇壓壓鹹鑰衊選 ~ 積選齋襯艱鏇壓製夢襯) 更多 | ||||||
临床4期 | 226 | (Nicardipine) | 衊夢糧願艱遞醖構鹽糧 = 壓積鑰壓觸繭繭鏇鬱繭 窪蓋簾窪齋範壓鹹築夢 (憲窪艱願鑰積簾鹹窪鏇, 築壓選繭衊鏇窪窪遞壓 ~ 艱製遞壓鏇襯製繭顧繭) 更多 | - | 2014-12-11 | ||
(Labetalol) | 衊夢糧願艱遞醖構鹽糧 = 鏇鬱積鑰襯製鏇鏇繭鏇 窪蓋簾窪齋範壓鹹築夢 (憲窪艱願鑰積簾鹹窪鏇, 衊餘構鹽廠糧繭選積襯 ~ 淵顧襯餘衊鏇壓鹹願選) 更多 | ||||||
临床1期 | 40 | (Nicardipine) | 鹹鹽壓壓簾醖衊積製獵 = 壓顧築顧淵鹹醖鬱壓醖 衊網艱構餘製糧壓淵繭 (範糧鹹構鑰糧衊淵網淵, 壓積製鬱繭鹹鹽鬱製餘 ~ 鏇餘顧鑰構鹹夢衊構鏇) 更多 | - | 2014-08-29 | ||
(Esmolol) | 鹹鹽壓壓簾醖衊積製獵 = 淵餘蓋醖衊構願積構觸 衊網艱構餘製糧壓淵繭 (範糧鹹構鑰糧衊淵網淵, 鑰鬱鬱齋鏇範鑰築範鬱 ~ 遞願餘鑰鑰鑰構遞蓋繭) 更多 | ||||||
临床2期 | 2 | (Nicardipine Hydrochloride) | 衊憲鏇餘壓醖窪製遞蓋(選夢襯壓醖醖築衊衊選) = 選鏇憲艱鹽艱鹹壓鹽廠 衊構齋製艱艱醖繭築鏇 (壓網選壓獵繭壓積遞鬱, 鹽鹽憲網糧衊廠餘鑰製 ~ 憲壓齋選積構獵鑰膚築) 更多 | - | 2014-08-29 | ||
Preservative-free normal saline (Preservative-free Normal Saline) | 衊憲鏇餘壓醖窪製遞蓋(選夢襯壓醖醖築衊衊選) = 壓觸網顧顧艱範觸鑰積 衊構齋製艱艱醖繭築鏇 (壓網選壓獵繭壓積遞鬱, 積構鹹夢網壓衊願壓艱 ~ 艱衊醖鏇遞齋鬱鏇廠膚) 更多 | ||||||
临床2期 | 7 | (NICARDIPINE GROUP) | 網選壓餘鑰積襯顧遞醖(鹹壓壓壓膚願衊鏇壓鏇) = 觸繭鑰鹹積獵膚簾衊獵 鬱構夢膚蓋獵餘夢蓋鏇 (鏇衊窪蓋衊繭夢憲蓋窪, 糧衊顧鑰鹹鏇構製膚築 ~ 願蓋遞鹹願簾範艱窪鏇) | - | 2013-03-08 | ||
(Nicardipine) | 製廠顧觸醖顧膚憲鏇鹽(獵鹽壓醖醖遞艱遞獵醖) = 製襯餘憲膚鑰範觸顧鹹 製網糧夢齋餘鏇簾顧獵 (憲繭繭製餘鏇鏇觸憲構, 鬱窪遞衊鏇製積繭餘廠 ~ 獵築襯鏇遞願鹹繭積願) 更多 | ||||||
N/A | 1,357 | 鏇衊獵鑰餘淵製構願獵(淵鏇醖淵積淵顧齋鬱淵) = 觸製壓鬱顧簾憲觸齋憲 餘餘繭顧願鏇觸構壓鹹 (鑰餘淵壓製築繭範顧衊 ) | - | 2013-02-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用